Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus[J]. Lancet Oncol 12(5):489–495

Article  PubMed  Google Scholar 

von Haehling S, Anker MS, Anker SD (2016) Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016[J]. J Cachexia Sarcopenia Muscle 7(5):507–509

Article  Google Scholar 

McDonald J, Sayers J, Anker SD et al (2023) Physical function endpoints in cancer cachexia clinical trials: systematic review 1 of the cachexia endpoints series[J]. J Cachexia Sarcopenia Muscle 14(5):1932–1948

Article  PubMed  PubMed Central  Google Scholar 

Argilés JM, López-Soriano FJ, Stemmler B et al (2019) Therapeutic strategies against cancer cachexia[J]. Eur J Transl Myology 29(1):7960

Article  Google Scholar 

Berenstein EG, Ortiz Z (2005) Megestrol acetate for the treatment of anorexia-cachexia syndrome[J]. Cochrane Database Syst Rev (2): CD004310. https://doi.org/10.1002/14651858.CD004310.pub2

Argilés JM, Anguera A, Stemmler B (2013) A new look at an old drug for the treatment of cancer cachexia: megestrol acetate[J]. Clin Nutr (Edinburgh, Scotland) 32(3):319–324

Article  Google Scholar 

Loprinzi CL, Schaid DJ, Dose AM et al (1993) Body-composition changes in patients who gain weight while receiving megestrol acetate[J]. J Clin Oncol: Off J Am Soc Clin Oncol 11(1):152–154

Article  Google Scholar 

PascualLópez A, RoquéiFiguls M, UrrútiaCuchi G et al (2004) Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome[J]. J Pain Symptom Manag 27(4):360–369

Article  Google Scholar 

Ruiz-García V, López-Briz E, Carbonell-Sanchis R et al (2018) Megestrol acetate for cachexia-anorexia syndrome. A systematic review[J]. J Cachex Sarcopenia Muscle 9(3):444–452

Article  Google Scholar 

Arends J, Strasser F, Gonella S et al (2021) Cancer cachexia in adult patients: ESMO clinical practice guidelines☆[J]. ESMO Open 6(3):100092

Article  PubMed  PubMed Central  Google Scholar 

Moertel CG, Schutt AJ, Reitemeier RJ et al (1974) Corticosteroid therapy of preterminal gastrointestinal cancer[J]. Cancer 33(6):1607–1609

Article  PubMed  Google Scholar 

Yavuzsen T, Davis MP, Walsh D et al (2005) Systematic review of the treatment of cancer-associated anorexia and weight loss[J]. J Clin Oncol: Off J Am Soc Clin Oncol 23(33):8500–8511

Article  Google Scholar 

Roeland EJ, Bohlke K, Baracos VE et al (2023) Cancer cachexia: ASCO guideline rapid recommendation update[J]. J Clin Oncol Wolters Kluwer 41(25):4178–4179

Article  Google Scholar 

Chow R, Chiu L, Navari R et al (2016) Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review[J]. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer 24(2):1001–1008

Article  Google Scholar 

Chelkeba L, Gidey K, Mamo A et al (2017) Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis[J]. Pharm Pract 15(1):877

Google Scholar 

Sandhya L, Devi Sreenivasan N, Goenka L et al (2023) Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer[J]. J Clin Oncol: Off J Am Soc Clin Oncol 41(14):2617–2627

Article  Google Scholar 

Poon IO, Ajewole V, Braun UK (2024) A review of olanzapine in the treatment of cancer anorexia-cachexia syndrome[J]. Pharmacy 12(1):34

Article  PubMed  PubMed Central  Google Scholar 

Radhakrishnan V, Pai V, Rajaraman S et al (2020) Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial[J]. Pediatr Blood Cancer 67(9):e28532

Article  PubMed  Google Scholar 

Mukhopadhyay S, Dutta P, Banerjee S et al (2021) Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study[J]. Futur Oncol (London, England) 17(16):2041–2056

Article  Google Scholar 

Vimolchalao V, Sakdejayont S, Wongchanapai P et al (2020) The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy[J]. Int J Clin Oncol 25(2):396–402

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews[J]. BMJ (Clin Res ed) 372:n71

Google Scholar 

Rm N, Mc B (2010) Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial[J]. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer Support Care Cancer 18(8):951–956

Article  Google Scholar 

Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials[J]. BMJ (Clin Res ed) 366:l4898

Google Scholar 

Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ : Brit Med J 336(7650):924–926

Article  PubMed  PubMed Central  Google Scholar 

Higgins JPT, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses[J]. BMJ (Clin Res ed) 327(7414):557–560

Article  Google Scholar 

Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial[J]. J Support Oncol 9(5):188–195

Article  PubMed  Google Scholar 

Rm N, Ck N, Se G (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy[J]. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer, Support Care Cancer 21(6):1655–1663

Article  Google Scholar 

Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting[J]. N Engl J Med 375(14):1395–1396

Article  Google Scholar 

Tienchaiananda P, Nipondhkit W, Maneenil K et al (2019) A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide[J]. Ann Palliat Med 8(4):372–380

Article  PubMed  Google Scholar 

Navari RM, Pywell CM, Le-Rademacher JG et al (2020) Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial[J]. JAMA Oncol 6(6):895–899

Article  PubMed  Google Scholar 

Yeo W, Lau TK, Li L et al (2020) A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients[J]. Breast (Edinburgh, Scotland) 50:30–38

Article  PubMed  Google Scholar 

Naik RD, V S, Singh V et al (2020) Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: investigator-initiated, randomized, open-label trial[J]. J Clin Oncol: Off J Am Soc Clin Oncol 38(32):3785–3793

Article  Google Scholar 

Clemons M, Dranitsaris G, Sienkiewicz M et al (2020) A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting[J]. Breast (Edinburgh, Scotland) 54:278–285

Article  PubMed  Google Scholar 

Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol 21(2):242–249

Article  PubMed  Google Scholar 

Maleki A, Ghadiyani M, Salamzadeh J et al (2020) Comparison of mirtazapine and olanzapine on nausea and vomiting following anthracycline-cyclophosphamide chemotherapy regimen in patients with breast cancer[J]. Iran J Pharm Res : IJPR 19(3):451–464

PubMed  PubMed Central  Google Scholar 

Mukhopadhyay S, Kwatra G, Alice KP et al (2017) Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study[J]. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer 25(1):145–154

Article  Google Scholar 

Moshayedi M, Salehifar E, Karami H et al (2021) Efficacy and safety of adding olanzapine to the standard preventive regimen for chemotherapy-induced nausea and vomiting in children: a randomized double-blind controlled trial[J]. Iran J Pharm Res: IJPR 20(1):318–326

PubMed  PubMed Central  Google Scholar 

Zhao Y, Yang Y, Gao F et al (2023) A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)[J]. eClinicalMedicine 55.((Zhao Y.; Yang Y.; Huang Y., huangyan@sysucc.org.cn; Zhang L., zhangli@sysucc.org.cn) Department of Medical Oncology of Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University, Guangzhou, China)

An Y, Zhang Z, Gu M et al (2023) Low dose olanzapine in the prevention and treatment of carboplatin induced nausea and vomiting: a prospective clinical randomized controlled trial[J]. Curr Pharm Des 29(23):1867–1874

Article  PubMed  Google Scholar 

Braiteh F, Dalal S, Khuwaja A et al (2008) Phase I pilot study of the safety and tolerability of olanzapine (OZA) for the treatment of cachexia in patients with advanced cancer[J]. J Clin Oncol, Wolters Kluwer 26(15_suppl):20529–20529